BioCentury | Oct 24, 2013
Strategy

Synaptic synopsis

...NR2B) Cerecor Inc. CERC-301 Phase I Depression NMDAR Naurex NRX-1074 Phase I Depression mGluR2 (GRM2) BrainCells Inc....
BioCentury | Dec 17, 2012
Clinical News

BCI-838: Phase I data

...BrainCells expects to start a proof-of-concept study in patients with treatment-resistant depression in early 2013. BrainCells...
...certain other Asian countries from Taisho under a 2007 deal (see BioCentury, Oct. 1, 2007). BrainCells Inc....
BioCentury | Dec 10, 2012
Company News

Sorbent management update

...Business: Renal, Cardiovascular Hired: Jason Levin as CBO, a newly created position, formerly CBO of BrainCells Inc. WIR...
BioCentury | Mar 12, 2012
Clinical News

BCI-838: Phase I data

...up to 900 mg oral BCI-838 were well tolerated with no severe adverse events reported. BrainCells...
...complete a Phase I trial evaluating multiple ascending-doses of BCI-838 in healthy volunteers by June. BrainCells...
...certain other Asian countries from Taisho under a 2007 deal (see BioCentury, Oct. 1, 2007). BrainCells Inc....
BioCentury | Apr 11, 2011
Company News

Depomed management update

...Neurology, Drug delivery Hired: James Schoeneck, a director, as president and CEO, formerly CEO of BrainCells Inc....
BioCentury | Aug 9, 2010
Company News

BrainCells, Proximagen deal

...II testing to treat schizophrenia. BrainCells is responsible for developing and marketing sabcomeline, for which BrainCells...
...had rights to sabcomeline from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) (see BioCentury, Jan. 11). BrainCells Inc....
BioCentury | Apr 8, 2010
Cover Story

Managing microglia in Alzheimer's

...Osherovich, L. SciBX 3 (14); doi:10.1038/scibx.2010.423 Published online April 8, 2010 Companies and Institutions Mentioned BrainCells Inc....
...is in preclinical development for cognitive disorders and depression by Taisho Pharmaceutical Co. Ltd. and BrainCells Inc....
...BrainCells in-licensed the compound from Taisho Pharmaceutical Co. Ltd. in 2007. Carrolee Barlow, CSO of BrainCells...
BioCentury | Apr 1, 2010
Distillery Therapeutics

Indication: Neurology

...include ongoing testing of the MGLUR2 and MGLUR3 antagonist BCI-632 in mouse models of AD. BrainCells Inc.'s...
BioCentury | Aug 3, 2009
Clinical News

BCI-952: Phase II data

...tolerated. Data were presented at the New Clinical Drug Evaluation Unit meeting in Hollywood, Fla. BrainCells Inc....
BioCentury | Jul 28, 2009
Clinical News

BrainCells reports BCI-952 data

BrainCells Inc. (San Diego, Calif.) reported mixed results from a Phase II trial of BCI-952 to treat major depressive disorder (MDD). A modified intent-to-treat (ITT) analysis showed the combination of low-dose buspirone and melatonin met...
Items per page:
1 - 10 of 29
BioCentury | Oct 24, 2013
Strategy

Synaptic synopsis

...NR2B) Cerecor Inc. CERC-301 Phase I Depression NMDAR Naurex NRX-1074 Phase I Depression mGluR2 (GRM2) BrainCells Inc....
BioCentury | Dec 17, 2012
Clinical News

BCI-838: Phase I data

...BrainCells expects to start a proof-of-concept study in patients with treatment-resistant depression in early 2013. BrainCells...
...certain other Asian countries from Taisho under a 2007 deal (see BioCentury, Oct. 1, 2007). BrainCells Inc....
BioCentury | Dec 10, 2012
Company News

Sorbent management update

...Business: Renal, Cardiovascular Hired: Jason Levin as CBO, a newly created position, formerly CBO of BrainCells Inc. WIR...
BioCentury | Mar 12, 2012
Clinical News

BCI-838: Phase I data

...up to 900 mg oral BCI-838 were well tolerated with no severe adverse events reported. BrainCells...
...complete a Phase I trial evaluating multiple ascending-doses of BCI-838 in healthy volunteers by June. BrainCells...
...certain other Asian countries from Taisho under a 2007 deal (see BioCentury, Oct. 1, 2007). BrainCells Inc....
BioCentury | Apr 11, 2011
Company News

Depomed management update

...Neurology, Drug delivery Hired: James Schoeneck, a director, as president and CEO, formerly CEO of BrainCells Inc....
BioCentury | Aug 9, 2010
Company News

BrainCells, Proximagen deal

...II testing to treat schizophrenia. BrainCells is responsible for developing and marketing sabcomeline, for which BrainCells...
...had rights to sabcomeline from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) (see BioCentury, Jan. 11). BrainCells Inc....
BioCentury | Apr 8, 2010
Cover Story

Managing microglia in Alzheimer's

...Osherovich, L. SciBX 3 (14); doi:10.1038/scibx.2010.423 Published online April 8, 2010 Companies and Institutions Mentioned BrainCells Inc....
...is in preclinical development for cognitive disorders and depression by Taisho Pharmaceutical Co. Ltd. and BrainCells Inc....
...BrainCells in-licensed the compound from Taisho Pharmaceutical Co. Ltd. in 2007. Carrolee Barlow, CSO of BrainCells...
BioCentury | Apr 1, 2010
Distillery Therapeutics

Indication: Neurology

...include ongoing testing of the MGLUR2 and MGLUR3 antagonist BCI-632 in mouse models of AD. BrainCells Inc.'s...
BioCentury | Aug 3, 2009
Clinical News

BCI-952: Phase II data

...tolerated. Data were presented at the New Clinical Drug Evaluation Unit meeting in Hollywood, Fla. BrainCells Inc....
BioCentury | Jul 28, 2009
Clinical News

BrainCells reports BCI-952 data

BrainCells Inc. (San Diego, Calif.) reported mixed results from a Phase II trial of BCI-952 to treat major depressive disorder (MDD). A modified intent-to-treat (ITT) analysis showed the combination of low-dose buspirone and melatonin met...
Items per page:
1 - 10 of 29